STADA ARZNEIMITTEL NPV(REGD) (VINKULIERT) (NASDAQ:STDAF)‘s stock had its “neutral” rating restated by investment analysts at DZ Bank AG in a research note issued to investors on Friday.

Separately, Zacks Investment Research raised shares of STADA ARZNEIMITTEL NPV(REGD) (VINKULIERT) from a “hold” rating to a “strong-buy” rating and set a $58.00 price objective on the stock in a research note on Thursday, December 29th.

Shares of STADA ARZNEIMITTEL NP (NASDAQ:STDAF) opened at 59.45 on Friday. The company’s 50-day moving average price is $57.83 and its 200 day moving average price is $53.03. The firm has a market cap of $3.74 billion and a P/E ratio of 29.09. STADA ARZNEIMITTEL NP has a 52 week low of $40.75 and a 52 week high of $62.20.

Your IP Address:

5 Day Chart for NASDAQ:STDAF

Receive News & Stock Ratings for STADA ARZNEIMITTEL NPV(REGD) (VINKULIERT) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STADA ARZNEIMITTEL NPV(REGD) (VINKULIERT) and related stocks with our FREE daily email newsletter.